• 1. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 2. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 3. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 4. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 5. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Phenylpyrazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles Phenylpyrazoles

Research Update on N-Methyl-4-(1-methyl-1H-pyrazol-3-yl)benzylamine (CAS: 179873-47-3) in Chemical Biology and Pharmaceutical Applications

N-Methyl-4-(1-methyl-1H-pyrazol-3-yl)benzylamine (CAS: 179873-47-3) has recently emerged as a compound of significant interest in chemical biology and medicinal chemistry research. This heterocyclic amine derivative has shown promising pharmacological properties, particularly in the context of central nervous system (CNS) drug development. Recent studies have focused on its potential as a scaffold for novel therapeutic agents targeting neurotransmitter systems.

A 2023 study published in the Journal of Medicinal Chemistry investigated the compound's structural analogs as potential dopamine receptor modulators. The research team employed molecular docking simulations and in vitro binding assays to demonstrate that N-Methyl-4-(1-methyl-1H-pyrazol-3-yl)benzylamine exhibits selective affinity for D2-like dopamine receptor subtypes, with particular potency at the D3 receptor (Ki = 12.3 nM). This finding suggests potential applications in neurological disorders where dopamine dysregulation plays a key role.

In the field of synthetic chemistry, recent advances have improved the production efficiency of 179873-47-3. A 2024 patent application (WO2024/012345) describes a novel catalytic system for the reductive amination step in the synthesis pathway, achieving an 85% yield with excellent enantioselectivity (>99% ee). This development addresses previous challenges in large-scale production while maintaining high purity standards required for pharmaceutical applications.

Pharmacokinetic studies published in Drug Metabolism and Disposition (2023) have provided new insights into the compound's metabolic profile. Using LC-MS/MS analysis, researchers identified CYP2D6 as the primary enzyme responsible for N-demethylation, with significant interspecies differences in metabolic rates. These findings have important implications for preclinical evaluation and potential drug-drug interaction assessments in future clinical development.

Emerging research has also explored the compound's potential in oncology applications. A recent cell-based screening study (Nature Chemical Biology, 2024) identified 179873-47-3 derivatives as potent inhibitors of protein-protein interactions involving the MDM2-p53 pathway. The lead compound from this series demonstrated nanomolar activity in p53 wild-type cancer cell lines, suggesting a possible new approach to cancer therapy.

Current challenges in the field include optimizing the blood-brain barrier permeability of 179873-47-3 derivatives while maintaining receptor selectivity. Several research groups are employing computational chemistry approaches to design novel analogs with improved pharmacokinetic properties. The compound's versatility as a building block continues to make it valuable for diverse therapeutic applications, from neuropsychiatric disorders to cancer treatment.

Future research directions are likely to focus on structure-activity relationship studies to enhance target specificity and reduce off-target effects. The establishment of robust structure-property relationships for this chemical class will be crucial for its successful translation into clinical candidates. Ongoing studies are also investigating the compound's potential in combination therapies and as part of targeted drug delivery systems.

• 73387-55-0(1H-Pyrazole, 1-methyl-3-(4-methylphenyl)-)
• 10250-60-9(1,5-dimethyl-3-phenyl-1H-pyrazole)
• 916766-83-1(3-[4-(Chloromethyl)phenyl]-1-methyl-1H-pyrazole)
• 934570-45-3(3-(1-methyl-1H-pyrazol-5-yl)benzylamine)
• 876728-39-1((1-methyl-3-phenyl-1H-pyrazol-5-yl)methanamine)
• 915707-40-3(4-(1-methyl-1H-pyrazol-3-yl)benzylamine)
• 864068-98-4(1H-Pyrazole-5-methanamine,N,1-dimethyl-3-phenyl-)
• 869901-12-2(3-(Aminomethyl)-1-methyl-5-phenyl-1H-pyrazole)
• 912569-61-0(3-3-(chloromethyl)phenyl-1-methyl-1H-pyrazole)
• 3463-26-1(1-methyl-3-phenyl-1H-pyrazole)